Ascites affects the benefit of carvedilol on patients with liver cirrhosis and esophageal and gastric varices
Clinical and Translational Science · 2024
DOI: 10.1111/cts.13889 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Ruiqi Xia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Carvedilol, Esophageal and Gastric Varices, Liver Cirrhosis, Ascites. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Esophageal and gastric varices (EGV) bleeding is a dangerous side effect of liver cirrhosis. Ascites may affect the effectiveness of carvedilol in preventing EGV rebleeding. A retrospective analysis was done on patients with EGV bleeding who visited our gastroenterology department between January 1, 2015, and October 29, 2020, and were given carvedilol therapy again. Patients were classified based on whether they had ascites. The primary outcome was EGV rebleeding. A total of 286 patients were included, with a median follow‐up of 24.0 (19.0–42.0) months, comprising those without ascites ( N = 155) and those with ascites ( N = 131). The mean age of the patients was 55.15 ± 12.44 years, and 177 (61.9%) of them were men. There were 162 (56.6%) Child‐Pugh A grades. The etiology of cirrhosis included 135 (47.2%) cases of hepatitis B. After carvedilol therapy, the patient's portal vein diameter (DPV) was widened ( p < 0.05), velocity of portal vein (VPV) was slowed ( p = 0.001). During the 1‐year follow‐up, patients with ascites had a substantially higher rebleeding rate than patients without ascites, with 24 (18.3%) versus 13 (8.4%), respectively ( p = 0.013). On univariate analysis, ascites was a risk factor for rebleeding ( p = 0.015). The multivariate analysis remained significant after adjusting for age, gender, etiology of cirrhosis, and previous endoscopic treatment, with OR of 2.37 (95% CI: 1.12–5.04; p = 0.025). Ascites was a risk factor for EGV rebleeding in patients undergoing carvedilol therapy. After carvedilol therapy, the patient's DPV was widened and VPV was slowed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Gastroenterology, Fujian Provincial Hospital, Fuzhou, China.
- Department of Gastroenterology, Minhang Hospital, Fudan University, Shanghai, China.
- Evidence-Based Medicine Centre, Fudan University, Shanghai, China.
ORCID-Profile: Ruiqi Xia, Ji Zhou, Mingyan Ji, Shuyue Wang, Xiaoqing Zeng, Shiyao Chen
Zitieren
APA
Xia, R., Wu, B., Zhou, J., Ji, M., Wang, S., Zeng, X., & Chen, S. (2024). Ascites affects the benefit of carvedilol on patients with liver cirrhosis and esophageal and gastric varices. Clinical and Translational Science. https://doi.org/10.1111/cts.13889
Vancouver
Xia R, Wu B, Zhou J, Ji M, Wang S, Zeng X, et al. Ascites affects the benefit of carvedilol on patients with liver cirrhosis and esophageal and gastric varices. Clinical and Translational Science. 2024. doi:10.1111/cts.13889
BibTeX
@article{Xia2024,
author = {Xia, Ruiqi and Wu, Bing and Zhou, Ji and Ji, Mingyan and Wang, Shuyue and Zeng, Xiaoqing and Chen, Shiyao},
title = {Ascites affects the benefit of carvedilol on patients with liver cirrhosis and esophageal and gastric varices},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.13889}
}
EUVIMED